Cargando…

Dual versus single long‐acting bronchodilator use could raise acute coronary syndrome risk by over 50%: A population‐based nested case–control study

BACKGROUND: Coronary heart disease occurs more frequently among patients with chronic obstructive pulmonary disease (COPD) compared to those without COPD. While some research suggests that long‐acting bronchodilators might confer an additional risk of acute coronary syndrome (ACS), information from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parkin, Lianne, Williams, Sheila, Sharples, Katrina, Barson, David, Horsburgh, Simon, Jackson, Rod, Wu, Billy, Dummer, Jack
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596666/ https://www.ncbi.nlm.nih.gov/pubmed/34289189 http://dx.doi.org/10.1111/joim.13348

Ejemplares similares

Is the use of two versus one long-acting bronchodilator by patients with COPD associated with a higher risk of acute coronary syndrome in real-world clinical practice?
por: Parkin, Lianne, et al.
Publicado: (2021)

Patterns of prescription medicine dispensing before and during pregnancy in New Zealand, 2005–2015
por: Donald, Sarah, et al.
Publicado: (2020)

Patterns of metformin monotherapy discontinuation and reinitiation in people with type 2 diabetes mellitus in New Zealand
por: Horsburgh, Simon, et al.
Publicado: (2021)

Simvastatin dose and acute kidney injury without concurrent serious muscle injury: A nationwide nested case-control study
por: Parkin, Lianne, et al.
Publicado: (2017)

Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database
por: Parkin, Lianne, et al.
Publicado: (2011)

Treatment pathways in people with type 2 diabetes mellitus: a nationwide cohort study of new users of metformin monotherapy in New Zealand
por: Guo, Joyce, et al.
Publicado: (2021)

A reply to questions raised about FEV(1)Q and bronchodilator responsiveness
por: Miller, Martin R., et al.
Publicado: (2023)

Inhaled bronchodilators and acute myocardial infarction: a nested case-control study
por: Lee, Chang-Hoon, et al.
Publicado: (2017)

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
por: Bateman, Eric D., et al.
Publicado: (2013)

Bronchodilator Response in Patients with Persistent Allergic Asthma Could Not Predict Airway Hyperresponsiveness
por: Petanjek, Bojana B, et al.
Publicado: (2007)

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?
por: Price, David, et al.
Publicado: (2014)

Statin adherence is lower in primary than secondary prevention: A national follow-up study of new users
por: Sigglekow, Finn, et al.
Publicado: (2020)

The future of bronchodilation: looking for new classes of bronchodilators
por: Cazzola, Mario, et al.
Publicado: (2019)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Dual Bronchodilator in the Era of Triple Therapy
por: Papaioannou, Andriana I, et al.
Publicado: (2020)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
por: Kang, Jieun, et al.
Publicado: (2017)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease
por: Donohue, James F, et al.
Publicado: (2011)

Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators
por: Nicolini, Antonello
Publicado: (2012)

Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2013)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
por: Matera, Maria Gabriella, et al.
Publicado: (2015)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
por: Singh, Dave, et al.
Publicado: (2019)

Mutation-inducing drugs could raise virus dangers
por: Le Page, Michael
Publicado: (2022)

Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives
por: Rhee, Chin Kook, et al.
Publicado: (2019)

The paradoxical response to short-acting bronchodilator administration in patients with chronic obstructive pulmonary disease
por: Shin, Hong-Joon, et al.
Publicado: (2021)

Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
por: Chin, Pik-Qi, et al.
Publicado: (2022)

Beyond Dual Bronchodilation – Triple Therapy, When and Why
por: Cazzola, Mario, et al.
Publicado: (2022)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Spirometry and Bronchodilator Test
por: Sim, Yun Su, et al.
Publicado: (2017)

Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial
por: Haney, Sarah, et al.
Publicado: (2005)

The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease
por: Kliber, Agnes, et al.
Publicado: (2010)

A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD
por: Jara, Michele, et al.
Publicado: (2012)

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
por: Bishwakarma, Raju, et al.
Publicado: (2017)

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
por: Halpin, David M. G., et al.
Publicado: (2016)

Short-acting β2-agonists (SABA) bronchodilator sales and outdoor mould in central France
por: Caillaud, D. M., et al.
Publicado: (2019)

A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use
por: Blank, Mei-Ling, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_inen1le743vg5url7f06rioh53